Souhaitez-vous accéder aux communiqués récents ?

Ipsen announces the availability of its 2025 Universal Registration Document PARIS, FRANCE, 1 APRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced that its 2025 Universal Registration Document...

WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation,...

Protein chip market grows to USD 4.79 Billion by 2035 at 6.89% CAGR, driven by proteomics research, and rising clinical diagnostics adoption.

Stage4Hope has announced a $2.5 million multi-year research commitment to Memorial Sloan Kettering Cancer Center (MSK) to support cancer research.

Exton, PA, March 31, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announced new findings from Launch Dynamix™: Aqvesme in Thalassemia, highlighting early physician perceptions and adoption...

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2...

     Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for...

PRINCETON, N.J. and SUZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in...

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 ...